Mechanism
Amylin is a short peptide hormone that the body releases alongside insulin when you eat. Eloralintide is an engineered, long-acting version of that signal.
What amylin does
Amylin is made by the beta cells of the pancreas and released together with insulin. Reviews of the field describe three main actions: it slows the emptying of the stomach, it suppresses the release of glucagon after meals, and it promotes the end of a meal through actions in the central nervous system, in particular the hindbrain. Together these shape how full a person feels and how quickly sugar from a meal reaches the blood.
[Verified V-56] Description of amylin physiology taken from the abstracts of three 2026 peer-reviewed reviews: Bailey, Flatt and Conlon, Peptides (PMID 41747885); Alhazmi and le Roux, Diabetes, Obesity and Metabolism (PMID 42452898); Fischer and Borner, Pharmacological Research (PMID 42586227). Checked 2026-10-02. Reviews summarise other work, so each statement is a general description, not a trial result.
Why natural amylin was not enough
Human amylin does not behave well as a medicine. The first approved amylin-based drug, pramlintide, was designed from the sequence of rat amylin, which does not clump the way the human version does. It was used as an add-on to insulin and, as one 2026 review puts it, was limited by modest efficacy and frequent dosing. That set the design goal for the next generation: a stable peptide that lasts long enough to be given once a week.
Receptors, and where eloralintide fits
Amylin acts on receptor complexes built from the calcitonin receptor and helper proteins. The combination of the calcitonin receptor with a helper called RAMP1 forms the amylin 1 receptor, abbreviated AMY1R; with RAMP3 it forms the amylin 3 receptor. Some long-acting analogues, such as cagrilintide, also act strongly on the calcitonin receptor itself. Eloralintide was reported to prefer the amylin 1 receptor, with roughly 11 to 12 fold greater potency there than at the calcitonin or amylin 3 receptors in human cell assays. Preferential means a leaning, not exclusivity. See how eloralintide works for the molecular design.
[Verified V-01, V-02] Eloralintide receptor figures confirmed against the full text of Briere et al. 2025 (2026-09-18). Receptor-complex description is general pharmacology; cagrilintide’s profile is described in its own sources and in the 2026 Peptides review.
The tolerability question
Nausea and other stomach effects are common when amylin-based medicines are started and the amount is stepped up, and they mostly settle with continued use, according to a 2026 review. A separate 2026 review argues that how a design engages the calcitonin receptor, how quickly drug levels rise and which brain circuits are recruited may decide whether reduced eating reflects ordinary fullness or an unpleasant, nauseating signal. That is a hypothesis that guides drug design, not a settled explanation. The trial figures for eloralintide are on the side effects page.
What this does not say
Knowing how amylin works does not show that any analogue is safe or effective in a given person. Eloralintide is investigational and not approved, and this page is background reading, not guidance for any use.
Related
Continue with the eloralintide mechanism, half-life and once-weekly dosing, or the other amylin-based programs in the metabolic research landscape.